LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 100

Search options

  1. Book: Marijuana and Madness

    Castle, David / D'Souza, Deepak Cyril / Murray, Robin

    2023  

    Size 256 p.
    Publisher Cambridge University Press
    Document type Book
    Note PDA Manuell_22
    Format 189 x 245 x 17
    ISBN 9781009305433 ; 1009305433
    Database PDA

    Kategorien

  2. Article: Cannabis, cannabinoids and psychosis: a balanced view.

    D'Souza, Deepak Cyril

    World psychiatry : official journal of the World Psychiatric Association (WPA)

    2023  Volume 22, Issue 2, Page(s) 231–232

    Language English
    Publishing date 2023-05-08
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2236130-3
    ISSN 2051-5545 ; 1723-8617
    ISSN (online) 2051-5545
    ISSN 1723-8617
    DOI 10.1002/wps.21075
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Editorial.

    D'Souza, Deepak Cyril / Curran, Helen Valerie

    Psychopharmacology

    2022  Volume 239, Issue 5, Page(s) 1143–1145

    Language English
    Publishing date 2022-05-11
    Publishing country Germany
    Document type Editorial
    ZDB-ID 130601-7
    ISSN 1432-2072 ; 0033-3158
    ISSN (online) 1432-2072
    ISSN 0033-3158
    DOI 10.1007/s00213-022-06110-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.

    Holze, Friederike / Singh, Nirmal / Liechti, Matthias E / D'Souza, Deepak Cyril

    Biological psychiatry. Cognitive neuroscience and neuroimaging

    2024  

    Abstract: Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential ... ...

    Abstract Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s) of action, pharmacokinetics, pharmacodynamics, efficacy, and safety were reviewed. While evidence for therapeutic indications, with the exception of psilocybin for depression, is still relatively scarce, we noted no differences in psychedelic effects beyond effect duration. Therefore, it remains unclear whether different receptor profiles contribute to the therapeutic potential of these compounds. More research is needed to differentiate these compounds in order to inform which compounds might be best for different therapeutic uses.
    Language English
    Publishing date 2024-02-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2879089-3
    ISSN 2451-9030 ; 2451-9022
    ISSN (online) 2451-9030
    ISSN 2451-9022
    DOI 10.1016/j.bpsc.2024.01.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Correction to: Psychedelics: Old trips, new destinations in psychopharmacology research.

    de Wit, Harriet / D'Souza, Deepak Cyril

    Psychopharmacology

    2022  Volume 239, Issue 6, Page(s) 1647

    Language English
    Publishing date 2022-05-19
    Publishing country Germany
    Document type Published Erratum
    ZDB-ID 130601-7
    ISSN 1432-2072 ; 0033-3158
    ISSN (online) 1432-2072
    ISSN 0033-3158
    DOI 10.1007/s00213-022-06157-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: The therapeutic potential of psychedelics.

    Schindler, Emmanuelle A D / D'Souza, Deepak Cyril

    Science (New York, N.Y.)

    2022  Volume 378, Issue 6624, Page(s) 1051–1053

    Abstract: The development of psychedelics as medicines faces several challenges. ...

    Abstract The development of psychedelics as medicines faces several challenges.
    MeSH term(s) Hallucinogens/pharmacology ; Hallucinogens/therapeutic use
    Chemical Substances Hallucinogens
    Language English
    Publishing date 2022-12-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 128410-1
    ISSN 1095-9203 ; 0036-8075
    ISSN (online) 1095-9203
    ISSN 0036-8075
    DOI 10.1126/science.abn5486
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Cannabis in psychiatric disorders: the cart before the horse?

    D'Souza, Deepak Cyril

    The lancet. Psychiatry

    2019  Volume 6, Issue 12, Page(s) 968–969

    MeSH term(s) Cannabinoids ; Cannabis ; Hallucinogens ; Humans ; Marijuana Abuse ; Mental Disorders
    Chemical Substances Cannabinoids ; Hallucinogens
    Language English
    Publishing date 2019-10-28
    Publishing country England
    Document type Journal Article ; Comment
    ISSN 2215-0374
    ISSN (online) 2215-0374
    DOI 10.1016/S2215-0366(19)30375-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Cannabis and Psychosis: Recent Epidemiological Findings Continuing the "Causality Debate".

    Ganesh, Suhas / D'Souza, Deepak Cyril

    The American journal of psychiatry

    2021  Volume 179, Issue 1, Page(s) 8–10

    MeSH term(s) Cannabis ; Causality ; Humans ; Marijuana Abuse/epidemiology ; Psychotic Disorders/epidemiology
    Language English
    Publishing date 2021-12-28
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 280045-7
    ISSN 1535-7228 ; 0002-953X
    ISSN (online) 1535-7228
    ISSN 0002-953X
    DOI 10.1176/appi.ajp.2021.21111126
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Exocannabinoids, Endocannabinoids, and Psychosis.

    Radhakrishnan, Rajiv / Ranganathan, Mohini / Skosnik, Patrick D / D'Souza, Deepak Cyril

    Biological psychiatry. Cognitive neuroscience and neuroimaging

    2021  Volume 6, Issue 6, Page(s) 600–602

    MeSH term(s) Endocannabinoids ; Humans ; Psychotic Disorders
    Chemical Substances Endocannabinoids
    Language English
    Publishing date 2021-06-07
    Publishing country United States
    Document type Introductory Journal Article
    ZDB-ID 2879089-3
    ISSN 2451-9030 ; 2451-9022
    ISSN (online) 2451-9030
    ISSN 2451-9022
    DOI 10.1016/j.bpsc.2021.04.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.

    Sloshower, Jordan / Zeifman, Richard J / Guss, Jeffrey / Krause, Robert / Safi-Aghdam, Hamideh / Pathania, Surbhi / Pittman, Brian / D'Souza, Deepak Cyril

    Scientific reports

    2024  Volume 14, Issue 1, Page(s) 8833

    Abstract: Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting ... ...

    Abstract Several phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD). However, the mechanisms underlying its often persisting beneficial effects remain unclear. Observational research suggests that improvements in psychological flexibility may mediate therapeutic effects. However, no psychedelic trials to date have substantiated this finding in a clinical sample. In an exploratory placebo-controlled, within-subject, fixed-order study, individuals with moderate to severe MDD were administered placebo (n = 19) followed by psilocybin (0.3 mg/kg) (n = 15) 4 weeks later. Dosing sessions were embedded within a manualized psychotherapy that incorporated principles of Acceptance and Commitment Therapy. Depression severity, psychological flexibility, mindfulness, and values-congruent living were measured over a 16-weeks study period. Psychological flexibility, several facets of mindfulness, and values-congruent living significantly improved following psilocybin and were maintained through week 16. Additionally, improvements in psychological flexibility and experiential acceptance were strongly associated with reductions in depression severity following psilocybin. These findings support the theoretical premise of integrating psilocybin treatment with psychotherapeutic platforms that target psychological flexibility and add to emerging evidence that increasing psychological flexibility may be an important putative mechanism of change in psilocybin-assisted therapy for MDD and potentially, other mental health conditions.
    MeSH term(s) Humans ; Psilocybin ; Depressive Disorder, Major/drug therapy ; Depression/drug therapy ; Acceptance and Commitment Therapy ; Hallucinogens
    Chemical Substances Psilocybin (2RV7212BP0) ; Hallucinogens
    Language English
    Publishing date 2024-04-17
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-024-58318-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top